CoChat

TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets

Open access
Bestle, Dorothea, Heindl, Miriam Ruth, Limburg, Hannah, van, Thuy Van Lam, Pilgram, Oliver, Moulton, Hong, Stein, David A., Hardes, Kornelia, Eickmann, Markus, Dolnik, Olga, Rohde, Cornelius, Becker, Stephan, Klenk, Hans-Dieter, Garten, Wolfgang, Steinmetzer, Torsten, Böttcher-Friebertshäuser, Eva · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
PreprintCited by 117

The DOI matches its Crossref record.

Abstract

In December 2019, a novel coronavirus named SARS-CoV-2 first reported in Wuhan, China, emerged and rapidly spread to numerous other countries globally, causing the current pandemic. SARS-CoV-2 causes acute infection of the respiratory tract (COVID-19) that can result in severe disease and lethality. Currently, there is no approved antiviral drug for treating COVID-19 patients and there is an urgent need for specific antiviral therapies and vaccines. In order for SARS-CoV-2 to enter cells, its surface glycoprotein spike (S) must be cleaved at two different sites by host cell proteases, which therefore represent potential drug targets. In the present study we investigated which host cell proteases activate the SARS-CoV-2 S protein in Calu-3 human airway epithelial cells. We show that S can be cleaved by both the proprotein convertase furin at the S1/S2 site and the transmembrane serine protease 2 (TMPRSS2) at the S2’ site. We demonstrate that TMPRSS2 is essential for activation of SARS-CoV-2 S in Calu-3 cells through antisense-mediated knockdown of TMPRSS2 expression. Further, we show that SARS-CoV-2 replication can be efficiently inhibited by two synthetic inhibitors of TMPRSS2 and also by the broad range serine protease inhibitor aprotinin. Additionally, SARS-CoV-2 replication was also strongly inhibited by the synthetic furin inhibitor MI-1851. Combining various TMPRSS2 inhibitors with MI-1851 produced more potent antiviral activity against SARS-CoV-2 than an equimolar amount of any single serine protease inhibitor. In contrast, inhibition of endosomal cathepsins by E64d did not affect virus replication. Our data demonstrate that both TMPRSS2 and furin are essential for SARS-CoV-2 activation in human airway cells and are promising drug targets for the treatment of COVID-19 either by targeting one of these proteases alone or by a combination of furin and TMPRSS2 inhibitors. Therefore, this approach has a high therapeutic potential for treatment of COVID-19.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2020.04.15.042085

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 66

  1. 10.1016/j.jconrel.2006.09.011 · DOI · Paper page
  2. 10.1128/JVI.02320-12 · DOI
  3. 10.1073/pnas.0809524106 · DOI · Paper page
  4. 10.1128/JVI.00415-08 · DOI · Paper page
  5. 10.1128/JVI.01118-06 · DOI · Paper page
  6. 10.1016/j.vaccine.2012.10.001 · DOI
  7. 10.1128/JVI.01294-10 · DOI · Paper page
  8. Böttcher-Friebertshäuser E . 2018. Membrane-Anchored Serine Proteases: Host Cell Factors in Proteolytic Activation of Viral Glycoproteins. In: Böttcher-Friebertshäuser E. , Garten W. , Klenk H. (eds) Activation of Viruses by Host Proteases. Springer, Cham, p.153–203. Review. · DOI
  9. 10.1074/jbc.R109.021006 · DOI · Paper page
  10. 10.1371/journal.ppat.1004502 · DOI · Paper page
  11. 2019, The S2 Subunit of QX-type Infectious Bronchitis Coronavirus Spike Protein Is an Essential Determinant of Neurotropism, Viruses, 11, E972, 10.3390/v11100972 · DOI
  12. 10.1016/j.antiviral.2020.104742 · DOI · Paper page
  13. 10.1016/j.virol.2006.02.003 · DOI · Paper page
  14. 2007, Morpholino Oligomers Targeting PB1 and NP Genes Enhance Survival of Mice Infected with Highly Pathogenic Influenza A H7N7 Virus, Journal of General Virology, 89, 939
  15. 10.1016/j.ejcb.2015.05.013 · DOI
  16. Garten W , Klenk HD. 2008. Cleavage activation of the influenza virus hemagglutinin and its role in pathogenesis. In: Klenk HD , Matrosovich MN , Stech J (eds) Avian Influenza. Karger, Basel, pp 156–167. Review. · DOI
  17. Garten, W. 2018. Characterization of Proprotein Convertases and Their Involvement in Virus Propagation. In: Böttcher-Friebertshäuser E ., Garten W. , Klenk H. (eds) Activation of Viruses by Host Proteases. Springer, Cham, p.205–248. Review. · DOI
  18. 10.1093/infdis/jiu407 · DOI · Paper page
  19. 10.1039/c2md20074k · DOI
  20. 10.1002/cmdc.201500103 · DOI
  21. 2013, Synthesis and characterization of novel fluorogenic substrates of coagulation factor XIII-A, Anal Biochem, 442, 223, 10.1016/j.ab.2013.07.043 · DOI
  22. 10.1371/journal.ppat.1003774 · DOI · Paper page
  23. 10.3390/v4040557 · DOI · Paper page
  24. Hierholzer JC , Killington RA. 1996. Virus Isolation and Quantitation. In: Mahy BWJ , Kangro HO , (eds). Virology Methods Manual. London, San Diego: Academic Press. pp. 24–32. · DOI · Paper page
  25. Hoffmann M , Hofmann-Winkler H , Pöhlmann S . 2018. Priming Time: How Cellular Proteases Arm Coronavirus Spike Proteins. In: Böttcher-Friebertshäuser E ., Garten W. , Klenk H. (eds) Activation of Viruses by Host Proteases. Springer, Cham, p.71–98. Review. · DOI · Paper page
  26. Hoffmann M , Kleine-Weber H , Schroeder S , Krüger N , Herrler T , Erichsen S , Schiergens TS , Herrler G , Wu NH , Nitsche A , Müller MA , Drosten C , Pöhlmann S . 2020. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. pii: S0092-8674(20)30229–4. · DOI · Paper page
  27. 2019, TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection, J Virol, 93, e01815
  28. 10.1074/jbc.M400484200 · DOI
  29. 10.1016/0006-291X(65)90749-7 · DOI
  30. 10.1128/JVI.00094-12 · DOI · Paper page
  31. 10.1128/MCB.26.3.965-975.2006 · DOI · Paper page
  32. 10.1016/0966-842X(94)90123-6 · DOI · Paper page
  33. 2018, Entry, Replication, Immune Evasion, and Neurotoxicity of Synthetically Engineered Bat-Borne Mumps Virus, Cell reports, 25, 312, 10.1016/j.celrep.2018.09.018 · DOI
  34. 10.1038/mt.2008.81 · DOI
  35. 2019, TMPRSS2 Is the Major Activating Protease of Influenza A Virus in Primary Human Airway Cells and Influenza B Virus in Human Type II Pneumocytes, J Virol, 93, e00649
  36. 10.1016/j.antiviral.2015.05.006 · DOI
  37. 10.1007/s00705-008-0067-0 · DOI
  38. 10.1128/JVI.00079-09 · DOI · Paper page
  39. 2018, Middle East Respiratory Syndrome Coronavirus Spike Protein Is Not Activated Directly by Cellular Furin during Viral Entry into Target Cells, J Virol, 92, e00683
  40. 10.1042/BJ20130101 · DOI
  41. 1994, Metabolic fate of 14C-camostat mesylate in man, rat and dog after intravenous administration, Xenobiotica, 24, 79, 10.3109/00498259409043223 · DOI
  42. 10.1016/j.virusres.2014.11.021 · DOI · Paper page
  43. 10.1016/j.bbamem.2010.02.012 · DOI · Paper page
  44. 10.1016/j.antiviral.2011.04.012 · DOI
  45. 10.1073/pnas.1608147113 · DOI · Paper page
  46. Rensi S , Altman RB , Liu T , Lo YC , McInnes G , Derry A , Keys A. Homology Modeling of TMPRSS2 Yields Candidate Drugs That May Inhibit Entry of SARS-CoV-2 into Human. https://chemrxiv.org/articles/Homolog (preprint submitted on 20.03.2020) · doi:10.26434/chemrxiv.12009582
  47. 10.1021/cr010168i · DOI · Paper page
  48. 10.1128/JVI.03677-13 · DOI · Paper page
  49. 10.1128/IAI.70.12.7136-7139.2002 · DOI
  50. 10.1128/IAI.72.1.602-605.2004 · DOI
  51. 2016, Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry, J Virol, 91, e01387
  52. 10.1128/JVI.01890-13 · DOI · Paper page
  53. 10.1016/j.virol.2017.11.012 · DOI · Paper page
  54. 10.1073/pnas.0505577102 · DOI · Paper page
  55. 2002, Pennington, M. W. Addition of o-aminobenzoic acid during Fmoc solid phase synthesis of a fluorogenic substrate containing 3-nitrotyrosine, Letters in Peptide Science, 9, 221, 10.1023/A:1024141823692 · doi:10.1023/a:1024141823692
  56. 10.2174/138161208786071290 · DOI
  57. Steinmetzer T , and Hardes, K. 2018. The Antiviral Potential of host protease inhibitors. In: Böttcher-Friebertshäuser E ., Garten W. , Klenk H. (eds) Activation of Viruses by Host Proteases. Springer, Cham, p.279–325. Review. · DOI
  58. 2020, Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding, J Med Chem, 63, 1445, 10.1021/acs.jmedchem.9b01060 · DOI
  59. 1979, Comparative clinical study of FOY and Trasylol in acute pancreatitis, Adv Exp Med Biol, 120B, 367
  60. 10.1128/JVI.03799-13 · DOI
  61. 2019, Design, Synthesis, and Characterization of Macrocyclic Inhibitors of the Proprotein Convertase Furin, ChemMedChem, 14, 673, 10.1002/cmdc.201800807 · DOI
  62. Walls AC , Park YJ , Tortorici MA , Wall A , McGuire AT , Veesler D. 2020. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. pii: S0092-8674(20)30262–2. · DOI · Paper page
  63. 10.1038/nature16988 · DOI · Paper page
  64. 10.1128/JVI.01412-08 · DOI
  65. 10.1016/j.antiviral.2011.07.014 · DOI
  66. 10.1016/j.antiviral.2015.01.011 · DOI · Paper page

Cited by

See all 117

Metadata

Authors
Bestle, D., Heindl, M. R., Limburg, H., van, T. V. L., Pilgram, O., Moulton, H., Stein, D. A., Hardes, K., Eickmann, M., Dolnik, O., Rohde, C., Becker, S., Klenk, H.-D., Garten, W., Steinmetzer, T., & Böttcher-Friebertshäuser, E.
Venue
bioRxiv (Cold Spring Harbor Laboratory)
Publisher
openRxiv
Published
2020-04-15
OpenAlex
W3016846892
Cited by
117
References
0
Type
posted content
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets. https://app.cochat.ai/papers/10.1101/2020.04.15.042085
The paper
Bestle, D., Heindl, M. R., Limburg, H., van, T. V. L., Pilgram, O., Moulton, H., Stein, D. A., Hardes, K., Eickmann, M., Dolnik, O., Rohde, C., Becker, S., Klenk, H.-D., Garten, W., Steinmetzer, T., & Böttcher-Friebertshäuser, E. (2020). TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2020.04.15.042085

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.